President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

Pliant and Acelyrin adopt poison pill measures to counter activist investor Kevin Tang's stock accumulation, aiming to ...

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...

Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning.

The late-stage biopharma said the plan will issue one right for each share of common stock as of the close of business on March 24. The rights will initially trade with its common stock, and will ...

Acelyrin (NASDAQ:SLRN) stock in focus as the company adopts a poison pill to counter rapid stock acquisition by Tang Capital Partners. Read more here.

Acelyrin, Inc. (NASDAQ:SLRN) is a biopharma company focused on the development and commercialization of life-changing drug therapies. This California-based company, incorporated in July 2020 ...

There are plenty of reasons to consider coming off the pill, from wanting to conceive to trying to get back in touch with your regular rhythms. But beware the people online who demonise hormonal ...

The board of directors at immunology-focused biopharma Acelyrin (Nasdaq: SLRN) has found that an unsolicited takeover bid from Concentra Biosciences is an inferior proposal to the planned merger with ...

LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN) and Alumis Inc. (Nasdaq: ALMS) today reaffirmed their commitment to merge in an all ...